Rapid and effective evaluation of cancer treatments

Biovica

Biovica is a biotechnology company whose patented technology platform, DiviTum, measures the cell growth rate of patients with solid cancer tumours. The test is designed to provide a measure of how fast cancer grows, as well as whether targeted cancer treatment is effective. Biovica has initially chosen to focus on evaluating the treatment effect on metastatic breast cancer. The company is in an early commercial phase and currently has sales to the research market. Commercial launch in 2020 is estimated for Europe and the United States.

Financials

BIOVICA

SEKm 2018 2019 2020
Sales 3 14 36
Sales growth (%) -8,2 470 150
EBITDA -16 -14 N/A
EBITDA margin (%) -558,9 -644 -94,9
EBIT adj -18 -19 -18
EBIT adj margin (%) -659,4 -776 -126,5
Pretax profit -19 -18 -6
EPS rep -1,1 -1,03 -0,32
EPS growth (%) -7,7 7,1 68,8
EPS adj -1,1 -1,03 -0,32
DPS 0 0 0
EV/EBITDA (x) -7,3 -12,4 158,3
EV/EBIT adj (x) -6,1 -9,3 -32
P/E (x) -8,2 -8,9 -28,4
P/E adj (x) -8,2 -8,9 -28,4
EV/sales (x) 47,1 11,8 4,8
FCF yield (%) -14,9 -15,4 -5,9
Dividend yield (%) 0 0 0
Net IB debt/EBITDA 2,6 -0,6 9,6

Main shareholders

Biovica

Main shareholders Share capital % Voting shares % Verified
Anders Rylander 22.4 % 33.6 % 14 Dec 2018
Gunnar Rylander 5.6 % 8.6 % 31 Dec 2018
Kristina Gronowitz 2.3 % 3.7 % 31 Dec 2018
Mats Danielsson 1.7 % 2.2 % 31 Dec 2017
Avanza Pension 4.1 % 2.2 % 31 Dec 2018
LYM Consulting AB 2.8 % 1.5 % 31 Dec 2018
Lars Holmqvist 2.3 % 1.2 % 31 Dec 2018
Nordnet Pensionsförsäkring 1.7 % 0.9 % 31 Dec 2018
Danica Pension 1.7 % 0.9 % 31 Dec 2018
Per Stålhandske 1.7 % 0.9 % 31 Dec 2018
Source: Holdings by Modular Finance AB

Insider list

Biovica

Name
Karin Mattsson
Arinvest AB
Adam Germunder
Cecilia Driving
Cecilia Driving
Cecilia Driving
Cecilia Driving
Cecilia Driving
Cecilia Driving
Arinvest AB
Show More